Eligibility for the Medicare GLP-1 Bridge will also be limited to Medicare beneficiaries who have not filled a prescription under their Part D plan for a GLP-1 in 2026, and who do not have a diagnosis with a condition that is a medically accepted indication for a GLP-1 drug that could be covered under Part D (specified by CMS as type 2 diabetes, obstructive sleep apnea (OSA), and noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH)), even if they otherwise meet the clinical criteria
Segmentation Overview Segmentation Overview Drug Exenatide Byetta Bydureon Liraglutide Victoza Lixisenatide Lyxumia Dulaglutide Trulicity Semaglutide Ozempic Geography Germany Spain Italy France United Kingdom Russia Rest of Europe Data Sources, Market Sizing, and Validation Data Sources, Market Sizing, and Validation Desk Research Desk work starts by mapping the treated patient pool and the therapy environment in Europe, before numbers are modeled
GLP-1 is released eating and lasts only about 1-2 minutes before an enzyme called DPP-4 breaks it down
Furthermore, 40.4% of ICSRs involved hospitalized patients, 2.7% resulted in patient mortality, 0.9% led to disability, and 2.8% caused life-threatening reactions, while only 1.7% classified as non-serious outcomes